SBA — Integrated Continuous Glucose Monitoring System With Sensor Containing Dexamethasone Acetate Class II

FDA Device Classification

Classification Details

Product Code
SBA
Device Class
Class II
Regulation Number
862.1357
Submission Type
Review Panel
CH
Medical Specialty
Clinical Chemistry
Implant
Yes

Definition

An integrated continuous glucose monitoring system (iCGM) with sensor containing dexamethasone acetate is intended to automatically measure glucose in bodily fluids continuously or frequently for a specified period of time. iCGM systems are designed to reliably and securely transmit glucose measurement data to digitally connected devices, including automated insulin dosing systems, and are intended to be used alone or in conjunction with these digitally connected medical devices for the purpose of managing a disease or condition related to glycemic control. The dexamethasone acetate coating is intended to reduce inflammation at the sensor insertion site.

Recent 510(k) Clearances

K-NumberApplicantDevice NameDate
K241335senseonics, incorporatedEversense 365 Continuous Glucose Monitoring (CGM) SystemSeptember 16, 2024
DEN230052senseonics, incorporatedEversense AP CGM SystemApril 29, 2024